openPR Logo
Press release

Johnson & Johnson Defends Withdrawal of PMA for Rejected Hips

02-20-2012 06:31 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen, LLP

Nadrich & Cohen, LLP reports that Johnson & Johnson is defending its withdrawal of a PMA for a rejected metal hip device that was reportedly sold overseas.

Los Angeles, CA, February 16, 2012 – The Johnson & Johnson Company is facing more criticism after a recent New York Times article revealed that the company continued to market a metal hip resurfacing system overseas, despite the fact that the FDA failed to approve the device. According to the Massachusetts Medical Devices Journal, a company spokesperson called the move a business decision.

Reportedly, the company had submitted an application for a metal hip resurfacing system that was similar to a metal hip replacement already being sold in the U.S. The company opted to withdraw its premarket approval application for the resurfacing system after receiving notice from the FDA that additional clinical data would be required in order to evaluate the device’s safety. According to the Times article, Johnson & Johnson continued to market the device to health professionals overseas but it is unclear whether the company disclosed the FDA’s nonapproval of the metal hips.

The withdrawal of the PMA came around the same time as health officials were questioning the safety of the device that was already on the market, the ASR hip, manufactured by the company’s DePuy Orthopaedics division. The ASR hip was approved under the FDA’s 510(k) system, which allows manufacturers to seek approval for a device without additional safety testing if they can prove that a substantially equivalent product is already on the market.

It is unclear how many patients may have received one of the rejected hips but it is believed that as many as 93,000 patients worldwide were implanted with one of the ASR hips. These devices have since been linked to a number of complications, including pain, swelling, loss of mobility and metallosis. Johnson & Johnson is currently facing numerous lawsuits from patients who claim they were injured by a DePuy hip.

Attorney Jeffrey Nadrich believes that there may be many more patients in the U.S. who are either unaware of the recall or have yet to experience complications caused by one of these devices. Patients who were injured after receiving a DePuy metal hip implant are encouraged to complete a MedWatch form by visiting the Food and Drug Administration’s website.

Nadrich & Cohen, LLP is offering confidential, no-cost consultations to patients across the country who believe they were harmed by a defective hip. Help is available by calling the firm’s injury hotline at 1-800-718-4658 or by completing an online case evaluation form at www.depuyhipreplacementlawyers.net.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California specializing in handling mass tort actions and representing individuals in cases involving pharmaceutical companies and medical device manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling DePuy and Zimmer hip claims, the firm is also investigating cases involving Yaz, Actos, Avandia, Fosamax, Paxil, Zoloft, Vaginal Mesh, Wright Conserve Hips, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and PPH and Depakote. For more information, visit www.personalinjurylawcal.com.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Johnson & Johnson Defends Withdrawal of PMA for Rejected Hips here

News-ID: 211384 • Views:

More Releases from Nadrich & Cohen, LLP

Actos Bladder Cancer Lawsuits Continue to Mount as Attorneys Push for Consolidat …
With new Actos bladder cancer lawsuits being filed every day, the plaintiffs and their attorneys are urging for the consolidation of these cases. Some 3500 Actos lawsuits have been filed in state and federal courts across the country, including Illinois, New York, New Jersey, Ohio and California. The law firm of Nadrich & Cohen LLP is currently investigating claims from Actos users in all 50 states who claim they developed
New Actos Bladder Cancer Resource Center Offers Answers to Concerned Patients
Los Angeles, CA, December 6, 2011 -- Nadrich & Cohen LLP, a prominent national law firm, has established a new website geared towards helping Actos users who developed bladder cancer after taking the drug. Visitors to the new site, www.SideEffectActos.com, can find the latest updates, news and information on the Actos bladder cancer litigation. The link between Actos and bladder cancer first came to light in September 2010, when the
New Vaginal Mesh Safety Recommendations Issued
National law firm Nadrich & Cohen LLP is endorsing new recommendations issued by the American College of Obstetricians and Gynecologists (ACOG) and the American Urogynecologic Society (AUGS) regarding the use of transvaginal mesh to treat pelvic organ prolapse in certain women. In a joint statement, the two organizations called for physicians to limit their use of vaginal mesh only to high-risk women for whom other treatment methods would not be
Actos Bladder Cancer Lawsuits Expected to Top 10,000
Los Angeles, CA, December 2, 2011 --- The number of lawsuits stemming from Actos bladder cancer claims may reach more than 10,000, according to a Bloomberg report. In response, national law firm Nadrich & Cohen, LLP has launched a new Actos bladder cancer resource website to assist patients in filing their claims. Visitors to www.SideEffectActos.com can read up on the link between Actos and bladder cancer, get the latest updates

All 5 Releases


More Releases for Johnson

Urgent Care Apps Market 2019 Analysis by Johnson & Johnson (Johnson & Johnson He …
"the Global Urgent Care Apps market is accounted for $312.93 million in 2017 and is expected to reach $6,382.75 million by 2026 growing at a CAGR of 39.8%. Growing demand owing to growing focus on patient-centric healthcare delivery and increase in penetration of 3G and 4G networks are some key factors influencing the market growth. However, poor internet connectivity in developing countries is restricting the growth of the market. In
Global Erythropoietin Market 2019 - Amgen, Johnson & Johnson, Roche
This new report by Eon Market Research, titled “Global Erythropoietin Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Erythropoietin industry at a global as well as regional and country level. Key facts analyzed in this report include the Erythropoietin market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Biotechnology Market - Development Outlook 2025 | Pfizer, Johnson & Johnson
Global Biotechnology Market: Overview The global biotechnology market is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. The advent of stem cell technology, nanotechnology, and cloning has also propelled this market substantially and is expected to continue aiding to this market in the years to come. However, the dearth of awareness among consumers
Wet Tissues Market 2017- Johnson & Johnson, SC Johnson, Clorox, Beiersdorf, 3M
Apex Research, recently published a detailed market research study focused on the "Wet Tissues Market" across the global, regional and country level. The report provides 360° analysis of "Wet Tissues Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Wet Tissues industry, and estimates the future trend of Wet Tissues market on
Cytokines Market 2017 - AbbVie, Johnson & Johnson, GlaxoSmithKline, Sanofi
Apex Research, recently published a detailed market research study focused on the "Cytokines Market" across the global, regional and country level. The report provides 360° analysis of "Cytokines Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Cytokines industry, and estimates the future trend of Cytokines market on the basis of this
Global Facial Wipes Sales Market 2017 - Beiersdorf, Johnson & Johnson, SC Johnso …
The Global Facial Wipes Sales Industry report gives a comprehensive account of the Global Facial Wipes Sales market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report. The report features an up-to-date data on key companies product details, revenue figures, and sales. The business model strategies of the key firms in the Facial Wipes Sales